Your browser doesn't support javascript.
loading
Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?
Tauber, M; Viguier, M; Le Gall, C; Smahi, A; Bachelez, H.
Affiliation
  • Tauber M; Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015, Paris, France; Department of Dermatology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Sorbonne Paris Cité Université Paris Diderot, Paris, France.
Br J Dermatol ; 170(5): 1198-9, 2014 May.
Article in En | MEDLINE | ID: mdl-24641215
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Interleukin / Antirheumatic Agents / Interleukin 1 Receptor Antagonist Protein Limits: Humans / Male Language: En Journal: Br J Dermatol Year: 2014 Type: Article Affiliation country: France
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Interleukin / Antirheumatic Agents / Interleukin 1 Receptor Antagonist Protein Limits: Humans / Male Language: En Journal: Br J Dermatol Year: 2014 Type: Article Affiliation country: France